These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 10.04.2020 and posted on 15.04.2020by Matthew Groves, Alexander Domling, Angel Jonathan Ruiz Moreno, Atilio Reyes Romero, Constantinos Neochoritis, Marco Velasco-Velázquez
De novo drug discovery of any therapeutic modality (e.g.
antibodies, vaccines or small molecules) historically takes years from
idea/preclinic to the market and it is therefore not a short-term
solution for the current SARS-CoV-2 pandemic. Therefore, drug
repurposing – the discovery novel indication areas for already approved
drugs - is perhaps the only approach able to yield a short term
relieve. Here we describe computational screening results suggesting
that certain members of the drug class of gliptins are inhibitors of the
two SARS-CoV-2 proteases 3CLpro and PLpro. The oral bioavailable
antidiabetic drug class of gliptins are safe and have been introduced
clinically since 2006 and used by millions of patients since then. Based
on our repurposing hypothesis the nitrile containing gliptins deserve
further investigation as potential anti-COVID19 drugs.